Overview
KYMR market data
Price History
KYMR price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for KYMR. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140Benzinga · Jul 16, 2026, 12:02 PM
Kymera Therapeutics shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform.Benzinga · Jul 13, 2026, 5:27 PM
RBC Capital Downgrades Kymera Therapeutics to Sector Perform, Raises Price Target to $115Benzinga · Jul 13, 2026, 2:08 PM
Kymera's CEO Sold $6 Million in Stock After a 170% RunThe Motley Fool · Jul 13, 2026, 11:00 AM
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125Benzinga · Jun 30, 2026, 3:00 PM
Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136Benzinga · Jun 29, 2026, 3:15 PM
B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155Benzinga · Jun 29, 2026, 2:40 PM
Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129Benzinga · Jun 26, 2026, 3:15 PM
Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis ProgramBenzinga · Jun 25, 2026, 5:25 PM
BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price TargetBenzinga · Jun 25, 2026, 4:25 PM